Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DSP-3077
- Development stage
- Phase 2
- Lead developer
- Sumitomo Pharma America
- Modality
- iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
- Administration
- Subretinal, Surgical Implantation
01
Overview
DSP-3077 is an allogeneic induced pluripotent stem cell (iPSC)-derived retinal sheet therapy developed by Sumitomo Pharma for the treatment of retinitis pigmentosa (RP). The therapeutic candidate consists of three-dimensional retinal tissue sheets generated from human iPSCs. These sheets are surgically transplanted into the subretinal space of the patient's eye. The mechanism of action involves the integration of the transplanted retinal tissue with the host retina to replace degenerated photoreceptor cells and restore or preserve visual function. This approach aims to address the underlying cellular loss in advanced retinitis pigmentosa, where traditional gene therapies may no longer be effective due to the absence of target cells. DSP-3077 is currently being evaluated in Phase 1/2 clinical trials to assess its safety, tolerability, and preliminary efficacy.
- Other names
- Allogeneic iPSC-derived retinal sheetsiPSC-derived retinal sheets
Beyond the preview
Go deeper on DSP-3077.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DSP-3077.